Get the Stockscreener App
0.5616
11.78%
0.0592
After Hours:
.55
-0.0116
-2.07%
Kazia Therapeutics Limited Adr stock is traded at $0.5616, with a volume of 3.34M.
It is up +11.78% in the last 24 hours and up +72.96% over the past month.
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.
See More
Previous Close:
$0.5024
Open:
$0.52
24h Volume:
3.34M
Relative Volume:
2.27
Market Cap:
$18.69M
Revenue:
-
Net Income/Loss:
$-13.52M
P/E Ratio:
-0.7589
EPS:
-0.74
Net Cash Flow:
$-10.03M
1W Performance:
+39.49%
1M Performance:
+72.96%
6M Performance:
+49.36%
1Y Performance:
-12.09%
1-Day Range:
$0.51
$0.6473
1-Week Range:
$0.328
$0.6473
52-Week Range:
$0.1866
$1.58
Kazia Therapeutics Limited Adr Stock (KZIA) Company Profile
Name
Kazia Therapeutics Limited Adr
Sector
Industry
Phone
01161298780088
Address
140 WICKS RD, NEW SOUTH WALES 2113, NSW
Kazia Therapeutics Limited Adr Stock (KZIA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-21 | Initiated | Maxim Group | Buy |
| Jan-05-21 | Initiated | H.C. Wainwright | Buy |
Kazia Therapeutics Limited Adr Stock (KZIA) Latest News
Ratios in Focus: Analyzing Kazia Therapeutics Limited ADR (KZIA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Kazia Therapeutics Stock Scheduled to Reverse Split on Monday, October 28th (NASDAQ:KZIA) - Defense World
SEC Form 424B3 filed by Kazia Therapeutics Limited - Quantisnow
Paxalisib shows promise in brain metastasis treatment - Investing.com
It makes sense and dollars to buy Kazia Therapeutics Limited ADR (KZIA) stock - SETE News
Market Recap: Kazia Therapeutics Limited ADR (KZIA)’s Positive Momentum, Closing at 0.43 - The Dwinnex
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American - StockTitan
Kazia Therapeutics Limited ADR (KZIA) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Kazia Therapeutics Limited ADR (KZIA) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
China Vanke Co., Ltd. (OTCMKTS:CHVKY) Short Interest Update - Defense World
Kazia Therapeutics (NASDAQ:KZIA) Stock Price Down 3.6% - Defense World
KZIAKazia Therapeutics Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium - StockTitan
The Psychology of Kazia Therapeutics Limited ADR Inc. (KZIA) Price Performance: Understanding Market Sentiment - The InvestChronicle
Financial Health Report: Kazia Therapeutics Limited ADR (KZIA)’s Ratios Tell a Tale - The Dwinnex
Take off with Kazia Therapeutics Limited ADR (KZIA): Get ready for trading - SETE News
Did Kazia Therapeutics Limited ADR (KZIA) perform well in the last session? - US Post News
Daily Progress: Kazia Therapeutics Limited ADR (KZIA) Drop -5.25, Closing at 0.35 - The Dwinnex
Kazia secures exclusive license for cancer therapy - Investing.com
KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER - StockTitan
Pfizer (NYSE:PFE) and Kazia Therapeutics (NASDAQ:KZIA) Critical Comparison - Defense World
Kazia Therapeutics Limited ADR (KZIA) stock analysis: A comprehensive overview - US Post News
Kazia Therapeutics Limited ADR (KZIA) Stock: A Year of Highs and Lows - The InvestChronicle
Kazia Therapeutics Limited ADR (KZIA) is a good investment, but the stock may be undervalued - US Post News
Kazia Therapeutics Limited ADR Inc. (KZIA) Price Performance: A Technical Analysis Perspective - The InvestChronicle
KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GR - GuruFocus.com
Investing in Kazia Therapeutics Limited ADR (KZIA) might be a great opportunity, but the stock is a bit undervalued - US Post News
Kazia Therapeutics Limited ADR (KZIA)’s Day in Review: Closing at 0.40, Up by 3.90 - The Dwinnex
Healthy Upside Potential: Kazia Therapeutics Limited ADR (KZIA) - SETE News
Analytical Overview: Kazia Therapeutics Limited ADR (KZIA)’s Ratios Tell a Financial Story - The Dwinnex
The Kazia Therapeutics Limited ADR (KZIA) had a good session last reading, didn’t it? - US Post News
OppFi Inc (OPFI)’s results reveal risk - US Post News
Kazia Therapeutics Limited ADR Inc. (KZIA) Price Performance: A Comparative Analysis with Competitors - The InvestChronicle
There is no way Kazia Therapeutics Limited ADR (KZIA) can keep these numbers up - SETE News
KZIA’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
What Analysts Were Expecting After Kazia Therapeutics Limited ADR (NASDAQ: KZIA) rose 15.50% - Stocks Register
Closing Strong: Kazia Therapeutics Limited ADR (KZIA) Ends at 0.32, Down -7.80 from Last Close - The Dwinnex
Kazia Therapeutics Limited ADR (KZIA) can make a big difference with a little luck - SETE News
Was there any good news for Kazia Therapeutics Limited ADR (KZIA) stock in the last session? - US Post News
In the Green: Kazia Therapeutics Limited ADR (KZIA) Closes at 0.40, Up/Down -3.38 from Previous Day - The Dwinnex
Short Interest in Kazia Therapeutics Limited (NASDAQ:KZIA) Increases By 7,076.2% - Defense World
Stock Market Recap: Kazia Therapeutics Limited ADR (KZIA) Concludes at 0.42, a 15.59 Surge/Decline - The Dwinnex
Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics - InvestorPlace
Wall Street Analyst Initiated Kazia Therapeutics Limited ADR [KZIA]. What else is Wall St. saying - The DBT News
Kazia Therapeutics Limited ADR (KZIA) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Closing Figures: Kazia Therapeutics Limited ADR (KZIA)’s Negative Finish at 0.53, Down -11.48 - The Dwinnex
Kazia Therapeutics (NASDAQ:KZIA) and Organogenesis (NASDAQ:ORGO) Head to Head Review - Defense World
Analyzing Organogenesis (NASDAQ:ORGO) & Kazia Therapeutics (NASDAQ:KZIA) - American Banking and Market News
Kazia Therapeutics Limited ADR (KZIA) Stock: Navigating a Year of Volatility - The InvestChronicle
KZIA’s Q2 earnings estimates: What investors need to know - US Post News
Daily Market Movement: Kazia Therapeutics Limited ADR (KZIA) Sees a 2.58 Increase, Closing at 0.57 - The Dwinnex
Kazia Therapeutics Limited Adr Stock (KZIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.35%
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):